Bristol-Myers Squibb Co. (BMY) Financials
Key financial figures for Bristol-Myers Squibb Co. (Q3 2026).
Bristol Myers Squibb raised 2026 revenue guidance to $49.75-$50.25 billion while non-GAAP EPS guidance was lowered to $6.35-$6.55 from $6.75-$7.00, with the guided Acquired IPRD and licensing impact widening to $(0.60) per share from $(0.02). Revenue of $13,069 million rose 7% from $12,222 million a year earlier (7% ex-FX); U.S. revenue of $9,074 million rose 9% and international revenue of $3,995 million rose 3%. GAAP diluted EPS was $1.05 (versus $1.08) and non-GAAP EPS was $1.35 (versus $1.63); both include a net $(0.58) per share impact from Acquired IPRD charges and licensing income, versus $(0.20) a year earlier. On the outlook: 2026 non-GAAP guidance as of October (versus July): total revenues of approximately $49.75 to $50.25 billion (from approximately $49.0 to $50.0 billion); non-GAAP diluted EPS of $6.35 to $6.55 (from $6.75 to $7.00), including a $(0.60) per share impact from Acquired IPRD charges and licensing income (from $(0.02)); gross margin approximately 69% to 70% and operating expenses approximately $16.5 billion, unchanged; other income/(expense) approximately $(650) million (from $(700) million); effective tax rate approximately 18%, unchanged; Eliquis worldwide revenue growth of 20% to 25%, unchanged. Figures are for Q3 2026, as Bristol Myers Squibb Company reported them.
- Revenue
- $13.1B
- Net Income
- $2.2B
- EPS
- $1.06
- Total Assets
- $88.8B
- Operating Cash Flow
- $4.2B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $13.1B | $2.2B | $1.05 | $3.8B | |
| Q2 FY2026 | $13.0B | $3.3B | $1.62 | $3.1B | |
| Q1 FY2026 | $11.5B | $2.7B | $1.31 | $757M | |
| Q4 FY2025 | $12.5B | $1.1B | $0.53 | $1.6B | |
| Q3 FY2025 | $12.2B | $2.2B | $1.08 | $6.0B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $48.2B | $7.1B | $3.46 | $12.8B | |
| FY2024 | $48.3B | -$8.9B | -$4.41 | $13.9B | |
| FY2023 | $45.0B | $8.0B | $3.86 | $12.7B |
Frequently asked questions
What was Bristol Myers Squibb Company's revenue last quarter?
Bristol Myers Squibb Company reported revenue of $13.07 billion for Q3 FY2026, up 6.9% from the same period a year earlier.
Is Bristol Myers Squibb Company profitable?
Yes. Bristol Myers Squibb Company reported net income of $2.16 billion for Q3 FY2026, a net margin of 16.54% on revenue.
How much free cash flow did Bristol Myers Squibb Company generate?
Bristol Myers Squibb Company generated free cash flow of $3.84 billion in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Bristol-Myers Squibb Co. on SentiSense, with up to forty quarters and twenty fiscal years of history.